The coral derived hydroxyapatite sphere is a popular, integrated orbital implant designed to provide improved motility of the ocular prosthesis following enucleation. Although the implant has rapidly become widely used by ophthalmologists, little information is available regarding the problems of this technique in a large series of cases. Experience with 250 consecutive cases of hydroxyapatite orbital implant use was reviewed and the problems of the implants and their management investigated specifically. The reasons for enucleation included uveal melanoma (157 cases), retinoblastoma (70 cases), blind painful eye (22 cases), and intraocular medulloepithelioma (one case). Earlier treatment to the eye was performed before enucleation in 47 cases and included repair of ruptured globe (17 cases), plaque radiotherapy (18 cases), external beam radiotherapy (six cases), and others (six cases). During a mean of 23 months' follow up (range 6-40 months), there have been no recognisable cases of orbital haemorrhage related to the implant, and no cases of implant extrusion or implant migration. There was one case of presumed orbital infection (culture negative) that resolved with intravenous antibiotics and the implant was retained within the orbit. Other problems included conjunctival thinning in eight cases managed by observation and prosthesis adjustment, and conjunctival erosion in four cases managed by combinations of scleral patch graft, conjunctival flap, and prosthesis adjustment. The conjunctival erosion was caused by a poorly fitting prosthesis in three cases and wound dehiscence in one case. The problem rate in eyes receiving prior radiotherapy or surgery was not increased. The hydroxyapatite integrated orbital implant is a well tolerated motility implant without the high rate of extrusion and infection seen with other motility implants. The prosthesis fit may contribute to the tolerance of the implant. (Br_J Ophthalmol 1994; 78: 702-706) Oncology Service, Wills
Integrated orbital implants are designed to provide improved motility of the ocular prosthesis.' This is accomplished by connecting the moving orbital implant powered by the extraocular muscles to the relatively stationery overlying prosthesis. Historically , there has been a general hesitancy by ophthalmic surgeons to use an integrated orbital implant after enucleation because it often became infected or extruded. Such problems with integrated orbital implants were common with the exposed implants that were used in the 1940s and 1950s.'`In order to allow direct integration of the implant with the overlying prosthesis, a portion of the anterior surface of these implants was purposely not covered by human tissue. Unfortunately this exposed portion ofthe implant served as a site for tissue infection, tissue erosion, and eventual implant extrusion. It was learned from these experiences that an integrated orbital implant should be buried, not exposed. It should be covered completely by conjunctiva so as to prevent the unacceptable complications of the earlier implants.
The hydroxyapatite orbital implant is a buried orbital implant that can be integrated to the overlying prosthesis."5 It was devised by Perry and associates who studied the performance of the implant initially in animals and later obtained approval by the Food and Drug Administration for use in humans in 1989.' To obtain maximal prosthesis, the implant can be connected to the prosthesis by a peg that is placed into a conjunctival lined orifice in the vascularised buried implant. 9 The vascularisation of the implant is encouraged by its totally porous framework and is important in preventing infection and extrusion. This is a tremendous improvement over the integrated orbital implants that were used in the past.
We report our experience with 250 consecutive cases of hydroxyapatite orbital implant placed after enucleation. We emphasise the problems of this procedure and their management.
Patients and methods
We reviewed the charts and examined prospectively all our patients who had a hydroxyapatite orbital implant placed after enucleation. We identified 250 consecutive patients who had the implant placed since we first employed it in January 1990 up to the end of the study period, December 1992. The implant was used only for patients who had enucleation and was not used after evisceration. The selection of patients suitable for the hydroxyapatite orbital implant has been discussed by us previously. 7 The conditions for implant evaluated in this study included ocular diagnosis before enucleation, reason 22 cases, and medulloepithelioma in one case. There were no cases of enucleation for endophthalmitis. The cause of the blind painful eye included complications of extensive trauma in 12 cases, neovascular glaucoma in four cases, large uveal metastases non-responsive to conservative measures in two cases, intraocular invasion of squamous cell carcinoma of the conjunctiva in one case, and massive tuberculoma of the uvea and sclera with dehiscence of the sclera in one case. '5 In two of the eyes with uveal melanoma, there was massive extraocular extension that required lateral orbitotomy and modified exenteration removing the globe and the pseudoencapsulated extraocular tumour. 6 The extraocular muscles and peripheral orbital tissue were preserved and a hydroxyapatite sphere was successfully employed.
Forty seven of the patients had earlier treatment before enucleation, which included shielded plaque radiotherapy in 18 cases, external beam radiotherapy to the globe and orbit in six cases, multiple surgical repairs for a traumatised ruptured globe in 17 cases, partial lamellar sclerouvectomy for a uveal tumour in five cases, and multiple conjunctival excisions for conjunctival squamous cell carcinoma in one case (Table 1) . It is calculated that the orbital tissue receives 0 to 200 cGy from a properly shielded iodine-125 plaque with radiation doses used for uveal melanoma. The orbital tissue received 4000 to 5000 cGy in those eyes treated with external beam radiotherapy. The surgical technique was minimally modified as needed for those patients who had earlier surgery. The patients who had prior procedures (including irradiation) on the affected eye experienced no excessive problems and they tolerated the implant well.
In all cases the implant was wrapped in sclera that was pretreated with antibiotics and povidone iodine. We did not use irradiated sclera. The implant was spherical in all cases and was not decapitated anteriorly or reshaped in any way. In children less than 6 months old we used a 16 mm implant depending on the orbital volume, in children 6 months to 3 years old we used an 18 mm implant, and in patients older than 3 years we used a 20 mm implant. We did not use a 22 mm implant in any case. Of the 250 cases, we considered 140 patients eligible candidates for peg placement (Table 2 ). Of the 140 eligible patients, 109 were satisfied with their cosmetic appearance and motility and preferred not to have the peg placed. A peg was successfully placed in the other 31 cases. We prefer to wait until the implant is 6 months from the time of placement to allow adequate fibrovascular ingrowth and we prefer the patient to be at least 6 years of age so that cooperation with the ocularist is adequate for ideal prosthesis revision. If these two criteria are not met then we consider the patient temporarily ineligible for peg placement.
Problems with the hydroxyapatite orbital implant were few and included conjunctival thinning without erosion in eight cases, conjunctival erosion in four cases, presumed orbital In all cases of conjunctival thinning the treatment was prosthesis adjustment and careful observation. In three of the four cases of conjunctival erosion the treatment was surgical repair and prosthesis adjustment. Those three cases had poorly fitting prostheses with pressure points on the conjunctival surface that led to the erosion 6, 7, and 12 months after enucleation, respectively. The erosion in these three cases measured approximately 4 mm in diameter and the underlying sclera was melted at the site of erosion. Two of the three cases were managed by the same ocularist and had a fairly flat posterior prosthesis vault that needed to be more highly vaulted (Fig 1) . The last of the three cases developed erosion 12 months after enucleation and orbital magnetic resonance imaging showed deficient vascular ingrowth within the central portion of the implant (Fig 2) . The fourth case of conjunctival erosion occurred 1 month after enucleation and was the result of inadequate wound closure. All cases of conjunctival erosion were repaired with conjunctival wound repair initially, three subsequently required a scleral patch graft/conjunctival flap for adequate closure.
The two cases of peg extrusion were first recognised at 1 and 7 months after peg placement. Both were caused by granulation tissue filling the orifice for the peg and pushing the peg out. Our recommendation was to remove the granulation tissue and replace the peg. In no cases did the peg simply fall out of its otherwise normal orifice. In three cases, there was a subtle but audible click of the peg on the back of the prosthesis in extreme gaze.
The case ofpresumed orbital infection, characterised by persistent mild pain and mucoid discharge, occurred 3 months after enucleation in a child with an upper respiratory illness. It was diagnosed and managed elsewhere and was found to be conjunctival swab culture negative and blood culture negative and resolved with intravenous antibiotics. The time and provides good biomechanical results. [17] [18] [19] [20] [21] [22] [23] Over the past century most orbital implants have been non-integrated -that is, not directly connected to the overlying prosthesis. The benefit of an integrated implant is that the ocular prosthesis has improved motility and appears more like a natural eye."8 The major advantages of orbital hydroxyapatite implant over prior integrated implants are: (1) it is less likely to develop infection owing to its vascularised buried state, (2) it is less likely to migrate or extrude because ofits transformation into living tissue by fibrovascular ingrowth, and (3) it tolerates the foreign body peg because of its conjunctivally lined orifice for the peg, preventing direct contact with the implant.
Our study has demonstrated that hydroxyapatite is well tolerated in the human orbit. Our rate of problems is low and primarily consists of minor conjunctival thinning or conjunctival erosion. We believe our success can be partly attributed to covering the implant with sclera, careful generous tissue closure over the implant, and the oculist's attention to vaulting the posterior surface of the prosthesis to prevent pressure necrosis. Although we originally did not modify the shape of the implant, we currently often shave the anterior portion of the hydroxyapatite sphere in order to alleviate the problem of conjunctival thinning and erosion.6
In assessing a patient with conjunctival thinning or erosion over an implant we It is comforting that most patients are satisfied with their motility and cosmetic appearance without peg placement. Even without the peg, the motion of the implant in the socket is often excellent since a portion of this motility is generally transferred to the prosthesis via conjunctival forniceal movement and conjunctival friction.7 Only 31 of the 140 eligible patients chose to have the peg placed. The problems of peg placement are few. Two patients had extrusion of the peg because of excessive granulation tissue that could be excised and repaired. There were no infections caused by the peg. Only one minor problem of a subtle audible peg click in and out of the ball and socket joint in extreme gaze was heard by three patients who had the peg in place. The sound was inaudible to anyone but the patient and was only heard by the patient when the gaze was extreme and the peg travelled further in the socket than the prosthesis could travel owing to the prosthesis size.
Hydroxyapatite orbital implant is well tolerated by all age groups with few problems. We suspect that the future will bring more improvements with this implant and the implant coverage. Fabricated mesh coverage rather than donor scleral coverage of the implant is being investigated. The eventual goal is to provide the patient with a well tolerated, moving artificial eye. 
